NRx Pharmaceuticals, Inc. announced the appointment of Mr. Michael Taylor to its Board of Directors and Ms. Anita Nunes as a Board Observer. Ms. Nunes is also slated to be appointed to the Board of Directors of HOPE Therapeutics, Inc., NRx's wholly-owned subsidiary.
Michael Taylor brings over 25 years of experience in global credit markets, special situations, and capital formation, having served as a Partner at the Adi Dassler International Family Office and Managing Director at Oppenheimer & Co. He joins as the Board Designee of Smith & Sauer, LLC, following a recently announced financing.
Anita Nunes, CEO and Co-Founder of Smith & Sauer, LLC, has over 20 years of executive experience, including driving investments in pioneering ventures and leading AI-driven solutions. Her extensive healthcare expertise from McKesson and Gilead will be integral to the growth of the HOPE clinic network.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.